9th Annual

Protein-Protein Interactions

Targeting PPIs for Therapeutic Interventions

April 19-20, 2016

Protein-Protein Interactions icon  

Protein-Protein Interactions (PPIs), or complexes of proteins, represent a growing area of interest in the drug discovery arena. PPIs control important cellular processes that are often the basis of disease when the interactions have gone awry. PPIs also represent a relatively new type of drug target, thus expanding the potential space in which to find new medicines. Typical protein targets have an enzymatic activity upon which high throughput screens can be developed for identifying small molecule drug candidates. PPI targets however, require either biophysical-based approaches to screen for inhibitors that cause changes in interactions, or structural knowledge of the PPI site to enable structure-based design of inhibitors. A drug originally found by a PPI screen has yet to reach the market. We are getting closer however, thanks to technological advances in biophysical approaches that have enabled screening against PPI targets.

Cambridge Healthtech Institute once again convenes leading scientists in the field to share their knowledge and address challenging questions in PPI-targeted drug design such as: should we inhibit the PPI directly or allosterically? Which interface should be targeted and how much of it? Should the inhibitor bind transiently or longer? Join your drug discovery and medicinal chemistry peers at Protein-Protein Interactions, a day-and-a-half meeting that is part of our larger Drug Discovery Chemistry event.

Topics will likely include:

  • Examples of PPI amenable cellular processes (ubiquitination, epigenetic regulation, protein homeostasis, immunomodulation)
  • NMR, SPR and other biophysical approaches used for screening against PPIs
  • Fragment-based campaigns for initial hit finding
  • Structure-based drug design efforts to optimize lead candidates
  • Examples of covalent, non-covalent, allosteric and direct PPI inhibitors or stabilizer in development
  • Discovery and optimization challenges unique to PPI drug development
  • Case studies on PPI-targeted campaigns (mostly in inflammation and cancer)

If you would like to submit a proposal to give a presentation at this meeting, please click here.

The deadline for submission is October 2, 2015

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

For more details on the conference, please contact:
Anjani Shah, Ph.D.
Conference Director
Cambridge Healthtech Institute
Phone: (914) 723-0255
Email: ashah@healthtech.com

For partnering & sponsorship information, please contact:
Carolyn Benton
Business Development Manager
Cambridge Healthtech Institute
Phone: (+1) 781-972-5412
Email: cbenton@healthtech.com